Based on the Denali Therapeutics Inc stock forecast from 9 analysts, the average analyst target price for Denali Therapeutics Inc is USD 38.13 over the next 12 months. Denali Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Denali Therapeutics Inc is Neutral, which is based on 5 positive signals and 6 negative signals. At the last closing, Denali Therapeutics Inc’s stock price was USD 28.45. Denali Therapeutics Inc’s stock price has changed by -3.89% over the past week, +6.04% over the past month and +48.72% over the last year.
No recent analyst target price found for Denali Therapeutics Inc
No recent average analyst rating found for Denali Therapeutics Inc
Company Overview Denali Therapeutics Inc
Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California. Read Less
Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs ...Read More
Frequently Asked Questions About Denali Therapeutics Inc (DNLI) Stock
Based on ratings from 9 analysts Denali Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 10 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on DNLI's stock to indicate if its a good dividend stock.
Based on targets from 9 analysts, the average taret price for DNLI is USD 38.13 over the next 12 months. The maximum analyst target price is USD 90 while the minimum anlayst target price is USD 26.
DNLI stock's Price/Earning ratio is 136.02.
Our analysis grades DNLI stock's Price / Earning ratio at F. This means that DNLI stock's Price/Earning ratio is above 92% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this DNLI may be a overvalued for its sector.
The last closing price of DNLI's stock was USD 28.45.
The most recent market capitalization for DNLI is USD 3.87B.
Based on targets from 9 analysts, the average taret price for DNLI is projected at USD 38.13 over the next 12 months.
This means that DNLI's stock price may go up by +34.03% over the next 12 months.
We can't find any ETFs which contains Denali Therapeutics Inc's stock.
As per our most recent records Denali Therapeutics Inc has 364 Employees.
Denali Therapeutics Inc's registered address is 161 Oyster Point Boulevard, South San Francisco, CA, United States, 94080.
You can get more information about it from Denali Therapeutics Inc's website at https://www.denalitherapeutics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Denali Therapeutics Inc (DNLI) Stock
Based on ratings from 9 analysts Denali Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 10 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on DNLI's stock to indicate if its a good dividend stock.
Based on targets from 9 analysts, the average taret price for DNLI is USD 38.13 over the next 12 months. The maximum analyst target price is USD 90 while the minimum anlayst target price is USD 26.
DNLI stock's Price/Earning ratio is 136.02.
Our analysis grades DNLI stock's Price / Earning ratio at F. This means that DNLI stock's Price/Earning ratio is above 92% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this DNLI may be a overvalued for its sector.
The last closing price of DNLI's stock was USD 28.45.
The most recent market capitalization for DNLI is USD 3.87B.
Based on targets from 9 analysts, the average taret price for DNLI is projected at USD 38.13 over the next 12 months.
This means that DNLI's stock price may go up by +34.03% over the next 12 months.
We can't find any ETFs which contains Denali Therapeutics Inc's stock.
As per our most recent records Denali Therapeutics Inc has 364 Employees.
Denali Therapeutics Inc's registered address is 161 Oyster Point Boulevard, South San Francisco, CA, United States, 94080.
You can get more information about it from Denali Therapeutics Inc's website at https://www.denalitherapeutics.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for DNLI !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
